Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Tuesday, October 07, 2025
Symbiosis Pharmaceutical Services has successfully completed qualification of its new FPD 50 Flexicon automated fill/finish line at its new commercial production facility in Stirling, Scotland.
read more
Symbiosis Pharmaceutical Services has appointed Wendy Cook as a Qualified Person (QP) to further strengthen its regulatory and quality leadership team.
read more
Thursday, November 06, 2025
Symbiosis Pharmaceutical Services has strengthened its business development team in the US with the dual appointments of Kevin O’Brien and LeeAnn Nguyen as Vice Presidents of Business Development for North America, and North America and Asia ...
read more
Symbiosis Pharmaceutical Services has manufactured their first 10,000 vial batch at the company’s new facility in Stirling, UK.
read more
Monday, September 09, 2024
Symbiosis Pharmaceutical Services Ltd. announced the purchase of new premises in Stirling, Scotland, UK. The additional space will significantly increase manufacturing capacity, strengthen the current Symbiosis commercial manufacturing service ...
read more
Symbiosis Pharmaceutical Service announced the purchase of new premises in Stirling, Scotland, UK.
read more
Monday, November 20, 2023
The recent merger of Symbio LLC and Dow Development Laboratories LLC with Proinnovera has given rise to Symbio Proinnovera, a dedicated dermatology-focused Contract Research Organization (CRO).
read more
Sygnature Discovery is strengthening its HTS and translational oncology service-offerings by investing £3 million in new instrumentation and equipment.
read more
Sygnature Discovery has appointed Dr. Nick Moore as Senior Director, Business Development, in a newly-created role to promote the
in vivo pharmacology and consultancy services offered by RenaSci.
read more
Thursday, September 10, 2020
Sygnature Discovery has appointed Dr. Andy Mead as Director and Head of Drug Abuse and Substance Use Disorders at its integrated in vivo pharmacology company, RenaSci.
read more
Tuesday, February 24, 2026
Sygnature Discovery, a drug discovery contract research organization (CRO), announced a strategic brand relaunch, including a new website.
read more
Monday, September 25, 2023
Sygnature Discovery and UBE Corporation have begun a collaboration on a Hit-to-Lead program to identify SHP2 degraders.
read more
Wednesday, April 15, 2020
Sygnature Group is supporting the Government’s COVID-19 testing strategy with the loan of a key piece of equipment.
read more
Sygnature Discovery announced a new addition to its leadership team, with the appointment of industry veteran Jade Dagher as General Manager for Canada.
read more
Monday, September 23, 2019
Sygnature Discovery has announced its US office has moved.
read more